Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2010 1
2013 1
2014 1
2017 1
2018 3
2019 5
2020 6
2021 4
2022 8
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.
Morelli M, Carbone ML, Scaglione GL, Scarponi C, Di Francesco V, Pallotta S, De Galitiis F, Rahimi S, Madonna S, Failla CM, Albanesi C. Morelli M, et al. Among authors: de galitiis f. Front Immunol. 2024 Mar 1;15:1346687. doi: 10.3389/fimmu.2024.1346687. eCollection 2024. Front Immunol. 2024. PMID: 38495872 Free PMC article.
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Luke JJ, et al. Among authors: de galitiis f. J Clin Oncol. 2024 Mar 7:JCO2302355. doi: 10.1200/JCO.23.02355. Online ahead of print. J Clin Oncol. 2024. PMID: 38452313
Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Falcone R, Verkhovskaia S, Di Pietro FR, Poti G, Samela T, Carbone ML, Morelli MF, Zappalà AR, di Rocco ZC, Morese R, Piesco G, Marchetti P, Failla CM, De Galitiis F. Falcone R, et al. Among authors: de galitiis f. Curr Oncol. 2024 Jan 22;31(1):588-597. doi: 10.3390/curroncol31010042. Curr Oncol. 2024. PMID: 38275835 Free PMC article.
The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.
Mezi S, Botticelli A, Scagnoli S, Pomati G, Fiscon G, De Galitiis F, Di Pietro FR, Verkhovskaia S, Amirhassankhani S, Pisegna S, Gentile G, Simmaco M, Gohlke B, Preissner R, Marchetti P. Mezi S, et al. Among authors: de galitiis f. Cancers (Basel). 2023 Sep 15;15(18):4587. doi: 10.3390/cancers15184587. Cancers (Basel). 2023. PMID: 37760556 Free PMC article.
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA, Di Giacomo AM, Chiarion Sileni V, Queirolo P, Spagnolo F, De Galitiis F, Cognetti F, Mandalà M, Guidoboni M, Rinaldi G, Depenni R, Consoli F, Troiani T, Guida M, Marconcini R, Ferrucci PF, Strippoli S, Fava P, Merelli B, Simeone E, Di Guardo L, Giannarelli D, Maio M, Quaglino P, Del Vecchio M. Ascierto PA, et al. Among authors: de galitiis f. Eur J Cancer. 2023 Sep;191:113246. doi: 10.1016/j.ejca.2023.113246. Epub 2023 Jul 19. Eur J Cancer. 2023. PMID: 37549531
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
Chiloiro S, Giampietro A, Bianchi A, Menotti S, Angelini F, Tartaglione T, Antonini Cappellini GC, De Galitiis F, Rossi E, Schinzari G, Scoppola A, Pontecorvi A, De Marinis L, Fleseriu M. Chiloiro S, et al. Among authors: de galitiis f. J Pers Med. 2023 Feb 26;13(3):415. doi: 10.3390/jpm13030415. J Pers Med. 2023. PMID: 36983597 Free PMC article.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA; KEYNOTE-716 Investigators. Long GV, et al. Among authors: de galitiis f. Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265502 Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA, Luke JJ, Long GV, Ascierto PA, Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, De Galitiis F, Ross MI, Eroglu Z, Chen K, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Kirkwood JM. Khattak MA, et al. Among authors: de galitiis f. Eur J Cancer. 2022 Nov;176:207-217. doi: 10.1016/j.ejca.2022.08.004. Epub 2022 Oct 3. Eur J Cancer. 2022. PMID: 36202690 Free article. Clinical Trial.
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.
Levati L, Bassi C, Mastroeni S, Lupini L, Antonini Cappellini GC, Bonmassar L, Alvino E, Caporali S, Lacal PM, Narducci MG, Molineris I, De Galitiis F, Negrini M, Russo G, D'Atri S. Levati L, et al. Among authors: de galitiis f. Cancers (Basel). 2022 Jul 29;14(15):3706. doi: 10.3390/cancers14153706. Cancers (Basel). 2022. PMID: 35954369 Free PMC article.
Cross-Cultural Adaptation and Preliminary Validation of Upper Limb Lymphedema Quality of Life Questionnaire (ULL-27) in Italian Female Patients with Breast Cancer-Related Lymphedema.
Samela T, Bartoletti R, Antinone V, Aloisi D, Papanikolaou ES, Quintavalle C, De Galitiis F, Abeni D, Marchetti P. Samela T, et al. Among authors: de galitiis f. Lymphat Res Biol. 2022 Dec;20(6):651-658. doi: 10.1089/lrb.2021.0080. Epub 2022 Apr 11. Lymphat Res Biol. 2022. PMID: 35404129
34 results